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Abstract
In T cells PKCh mediates the activation of critical signals downstream of TCR/CD28 stimulation. We investigated the
molecular mechanisms by which PKCh regulates NFkB transactivation by examining PKCh/b single and double knockout
mice and observed a redundant involvement of PKCh and PKCb in this signaling pathway. Mechanistically, we define a
PKCh-CYLD protein complex and an interaction between the positive PKCh/b and the negative CYLD signaling pathways
that both converge at the level of TAK1/IKK/I-kBa/NFkB and NFAT transactivation. In Jurkat leukemic T cells, CYLD is
endoproteolytically processed in the initial minutes of stimulation by the paracaspase MALT1 in a PKC-dependent fashion,
which is required for robust IL-2 transcription. However, in primary T cells, CYLD processing occurs with different kinetics
and an altered dependence on PKC. The formation of a direct PKCh/CYLD complex appears to regulate the short-term
spatial distribution of CYLD, subsequently affecting NFkB and NFAT repressional activity of CYLD prior to its MALT1-
dependent inactivation. Taken together, our study establishes CYLD as a new and critical PKCh interactor in T cells and
reveals that antagonistic PKCh/b-CYLD crosstalk is crucial for the adjustment of immune thresholds in primary mouse CD3+
T cells.
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Introduction
The central role of PKCh in signal transduction pathways
during an adaptive immune response has extensively focused on
the exact biochemical mechanisms of PKCh function (reviewed in
[1–3]). A recent study by Kong et al. identified the structural
requirement in PKCh for its localization to the immunological
synapse as a prerequisite for activation of downstream signaling
[4]. Several transcription factors essential for the T cell activation
response (i.e. NFkB, AP1, and NFAT) are regulated by PKCh
[5,6]. In vivo analysis of PKCh 2/2 mice revealed the importance
of PKCh for Th2- [7] and Th17-mediated immune responses [8,9]
but not for host-protective antiviral responses [10]. Nevertheless,
despite a profound understanding of the cellular role of PKCh,
little is known about its molecular function, specifically the effector
proteins downstream of PKCh during T cell activation.
Ubiquitylation and deubiquitylation are established posttrans-
lational mechanisms for regulating immune responses, as well as
the development and activation of immune cells. The tumor
suppressor gene CYLD encodes an evolutionary conserved and
ubiquitously expressed protein of approximately 120 kDa and was
originally discovered as gene mutated in familial cylindromatosis,
an autosomal dominant inherited disease characterized by the
development of multiple benign skin tumors, principally on the
head and neck [11]. Functionally it is a deubiquitylating enzyme
(DUB) which removes mainly K63-linked polyubiquitin chains
from several specific substrates, influencing in a negative way the
activation status and/or spatial distribution of these target proteins
in different signaling pathways. Numerous studies both in vitro
and in vivo provided us with new insights in its established
function as an important negative regulator of inflammatory
responses, by counteracting the aberrant activation of NFkB
signaling: Cyld2/2 animals spontaneously develop intestinal
inflammation and autoimmune symptoms due to the constitutive
activation of the TAK1/IKK/IkBa axis [12,13]; the study of Lim
et al. described a CYLD dependent negative NFkB regulation
during bacteria induced lung inflammation in mice via deubiqui-
tylation of TRAF6 and TRAF7 [14]; moreover, the same scientific
group showed that Cyld knockout mice are protected from
Streptococcus pneumonia infection and lethality via a negative
crosstalk with p38 MAPK [15]; a synergistic crosstalk between the
E3 ligase Itch and CYLD for TAK1 inactivation and termination
of tumor necrose factor dependent inflammatory signaling was
recently described [16].
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Figure 1. Overlapping roles of PKCh and PKCb in NFkB and NFAT transactivation processes in primary mouse CD3+ T cells. (A) PKCb
expression is upregulated in whole cell extracts of peripheral CD3+ T cells derived from PKCh-deficient mice. (B) The PKC isoform expression profile in
whole cell extracts of naive thymocytes (Thy) and peripheral CD3+ T cells derived from wild-type and PKCh/b2/2 mice. PKCh/b inhibition leads to an
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CYLD plays also an essential role in regulating T cell
development and activation. Cyld-deficient mice show a delayed
thymocyte development due to a constitutively K48-ubiquitylated
and degraded LCK protein [17]. In addition, Cyld-deficient T cells
are hyperresponsive to TCR/CD28 stimulation and CYLD has
been firmly established as negative regulator of NFkB and JNK
activation in response to antigen receptor activation in T cells
[12,13,18].
In the current study, we defined physiologically redundant roles
for the PKCh and PKCb isotypes in TCR/CD28-dependent
NFkB and NFAT transactivation by examining PKCh/b single
and double knockout mouse lines. Additionally, we provide
experimental evidence that a constitutive interaction of PKCh
with CYLD apparently leads to CYLD sequestration that affects
the transactivation of the critical transcription factors NFkB and
NFAT. Therefore, the results described here elucidate some
aspects of PKCh and PKCb function during TCR activation and
the processes that modulate CYLD function upstream of NFkB
and NFAT activation in primary CD3+ T lymphocytes.
Materials and Methods
Mice
PKCh/b knockout mice are viable, fertile and were generated by
crossing PKCh [5] and PKCb [19] single knockout mice. The
generation of Cyld-deficient mice was described previously [20]. All
mice were on a C57Bl/6 background and housed (under SPF
conditions) at the mouse facility of the Medical University of
Innsbruck. All animal experiments were performed in accordance
with the Austria ‘‘Tierversuchsgesetz’’ (BGBI. Nr. 501/1988
i.d.g.F.) and have been granted by the Bundesministerium fu¨r
Bildung, Wissenschaft und Kultur (bm:bwk).
Plasmids and Reagents
Strep-HA-tagged PKCh and Cyld cDNAs (full-length and
R324A mutant) were cloned into pEF-Neo. Vectors expressing
full-length Flag-tagged wild-type CYLD or N- or C- terminally
truncated forms of CYLD (encoding residues 1–212, 318–956 and
587–986 of CYLD) were described previously [21].
The pan-PKC low molecular weight inhibitor LMWI [22] was
provided by NYCOMED GmbH, and the tetrapeptide inhibitor
z-VRPR-fmk (MALT1 LMWI) was a gift from Dr. Margot
Thome.
Cell Culture and Transfections
Jurkat-TAg cells [23] (a kind gift from G.R. Crabtree, Stanford
University, CA) were maintained in RPMI medium supplemented
with 10% FCS (Life Technologies, Inc.) and antibiotics. Transient
transfection of cells with 20 mg of plasmids encoding GFP, wild-
type Cyld or a cleavage-resistant R324A Cyld mutant was
performed by electroporation with a BTX-T820 Electro Square
Porator (ITC, Biotech, Heidelberg, Germany) apparatus under
predetermined optimal conditions: 26107 cells at 450 V/cm and
five pulses of 99 ms.
HEK293T cells were cultured in Dulbecco’s Modified Eagle’s
Medium supplemented with 10% FCS, 2 mM L-glutamine, and
100 mg/ml penicillin–streptomycin. HEK293T cells were trans-
fected using MetafecteneTM transfection reagent according to the
manufacturer instructions.
Primary human T cells were purified from PBMCs (isolated by
standard Hypaque–Ficoll separation from whole blood samples)
with the Pan T Cell Isolation Kit (Miltenyi Biotec) according to the
manufacturer instructions.
Primary mouse CD3+ T cells were purified from pooled spleens
and lymph nodes with mouse T cell enrichment columns (R&D
Systems). T cell populations were typically 95% CD3+ as
determined by staining and flow cytometry.
increased NF-kB and NFAT transactivation defect in T cells. (C) The nuclear extracts of resting and stimulated (overnight) wild-type, PKCh2/2, PKCb2/2
and PKCh/b2/2 CD3+ T cells were probed for DNA binding to radio-labeled probes containing NFkB and NFAT binding site sequences, as indicated.
One representative experiment of three is shown. (D) Impaired nuclear import of p50, p65 and NFAT in activated PKCh/b2-deficient T cells. Nuclear
extracts of resting and stimulated (overnight) wild-type, PKCh2/2, PKCb2/2 and PKCh/b2/2 CD3+ T cells were probed for p65, p50 and NFAT using
immunoblot assays. DNA polymerase served as the loading control. One representative experiment of three is shown. (E) Effect of PKCh/b inhibition
on proximal phosphorylation events after a brief stimulation. Western blot analysis was performed with cytosolic extracts from wild-type, PKCh2/2,
PKCb2/2 and PKCh/b2/2 CD3+ T cells. CD3+ T cells were stimulated with anti-CD3/anti-CD28 and probed at different time points for the
phosphorylation status of (p)S-32 IkBa, (p)S-473 AKT and (p)ERK1/2, as indicated. Fyn served as loading control. One representative experiment of
three is shown. Protein phosphorylation levels were relatively quantitated by densitometric analysis. Numbers beneath bands indicate fold change
compared to wt control after normalization to FYN.
doi:10.1371/journal.pone.0053709.g001
Table 1. Flow cytometric analyses of the cellularity of the
thymus, spleen and lymph nodes from wild-type and PKCh/
b2/2 mice.
Thymus CD3+ CD19+ CD4+ CD8+ CD4+CD8+
wt 17,0562,29 0,0960,05 5,2161,50 2,1161,47 89,7662,63
PKCh/b2/2 11,0863,51 0,2160,07 2,9360,05 1,4660,71 93,9561,90
Spleen CD3+ CD19+ CD4+ CD8+ CD4+CD8+
wt 22,8468,57 66,86616,6317,1664,59 9,8962,52 0,9060,98
PKCh/b2/2 26,5963,79 63,3765,24 14,9762,33 13,7061,92 0,8860,72
Lymphnodes CD3+ CD19+ CD4+ CD8+ CD4+CD8+
wt 53,3160,56 37,9262,28 36,4960,30 20,8160,34 1,5160,73
PKCh/b2/2 53,1461,31 39,8460,37 31,7461,91 24,5063,27 1,0960,37
Surface expression of CD3, CD4, CD8 and CD19 were measured by flow
cytometry; the relative fluorescence intensities are indicated as a percentage of
positive cells. The results shown are the mean6SE of three independent
experiments.
doi:10.1371/journal.pone.0053709.t001
Table 2. Absolute cell numbers of thymic populations from
wild-type and PKCh/b2/2 mice.
CD3high CD4+ CD8+ CD4+CD8+
wt 27,161,3 8,261,6 3,362,0 143,8616,9
PKCh/b2/2 17,262,5 4,760,9 2,260,7 150,6629,6
Absolute cell numbers of thymic populations (x106). The results shown are the
mean6SE of three independent experiments.
doi:10.1371/journal.pone.0053709.t002
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Analysis of Proliferative Response and IL-2 Cytokine
Production
For in vitro proliferation, 56105 T cells in 200 ml proliferation
medium (RPMI supplemented with 10% FCS, 2 mM L-glutamine
and 50 units/ml penicillin/streptomycin) were added in duplicate
to 96-well plates precoated with anti-CD3 antibody (clone 2C11,
5 mg/ml) and soluble anti-CD28 (1 mg/ml; BD Bioscience) was
added. For TCR-independent T cell stimulation, 10 ng/ml
Phorbol 12,13-dibutyrate (PDBu) and 125 ng/ml of the calcium
ionophore ionomycin were added to the media. Cells were
harvested on filters after a 64 h stimulation period, pulsed with
H3-thymidine (1 mCi/well) in the final 16 h and the incorporation
of H3-thymidine was measured with a Matrix 96 direct b counter
system.
For short time stimulation, cells were activated by the addition
of anti-CD3 and anti-CD28 (or PDBu and ionomycin), both in
soluble form. For crosslinking, anti-hamster IgG1 (clone HIG-632)
was used.
IL-2 production in mouse CD3+ T cells after antibody
stimulation was determined by BioPlex technology (BioRad
Laboratories) from the supernatant.
Western Blot Analysis
Cells were lysed in ice-cold lysis buffer [5 mM Na3VO4, 5 mM
NaP2P, 5 mM NaF, 5 mM EDTA, 150 mM NaCl, 50 mM Tris
(pH 7.3), 2% NP-40, 50 mg/ml aprotinin and leupeptin] and
centrifuged at 15,0006g for 15 min at 4uC. Protein lysates were
subjected to immunoblotting using antibodies against NFATc1
(Affinity Bioreagents), (p)S473 AKT, (p)ERK, ERK, (p)T183/
Figure 2. PKCh and PKCb synergistically regulate TAK1 and JNK activation. (A) Defective Tak1 and JNK activation in PKCh/b-deficient CD3+
cells. Cytosolic extracts of PDBu- and ionomycin-stimulated wild-type and PKCh/b2/2 CD3+ T cells were probed for the phosphorylation status of
TAK1, JNK and ERK1/2, as indicated. Actin served as loading control. One representative experiment of three is shown. (B) PKC enzymatic activity
influences TAK1 and JNK activation status. The cytosolic extracts of PDBu- and ionomycin-stimulated, pan-PKC LMWI pretreated, or untreated control
wild-type CD3+ T cells were probed for the phosphorylation status of Tak1, JNK and ERK1/2, as indicated. Actin served as loading control. One
representative experiment of three is shown.
doi:10.1371/journal.pone.0053709.g002
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Figure 3. T cells from Cyld2/2mice exhibit hyper-responsiveness to TCR stimulation. (A) Naive wild-type and Cyld deficient CD3+ cells were
stimulated overnight (16 h) with the indicated amount of plate-bound anti-CD3 and soluble anti-CD28. Cytokines in the supernatants were measured
using Bioplex suspension array technology. (B) Nuclear extracts were isolated from unstimulated and CD3/CD28-stimulated CD3+ T cells from wild-
type control and Cyld2/2 mice. EMSA was performed to determine the activity of NFAT and NFkB. The same nuclear extracts were probed for NFAT
and DNA polymerase, using immunoblot assays, the latter one served as the loading control. (C) Purified naive peripheral CD3+ T cells from wild-type
and Cyld2/2 mice were stimulated with anti-CD3 and anti-CD28 for the indicated time periods. Immunoblotting assays were performed using the
PKCh/ß and CYLD Signaling Crosstalk
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Y185 JNK, JNK, p50, p65, (p)Y-783 PLCc1, (p)T184/T187Tak1,
Tak1 (all from Cell Signaling), PKCb, PKCh (both from BD
Transduction Laboratories), actin, Cyld (E10), DNA polymerase
and Fyn (all from Santa Cruz Biotechnology). The Cyld antibody
recognizing the NH2-terminal region of Cyld was described
previously [20].
Co-immunoprecipitation Analysis
For co-immunoprecipitation, 16107 primary mouse T cells (or
16106 transiently transfected HEK293T cells) were lysed in
400 ml of immunoprecipitation buffer [5 mM Na3VO4, 5 mM
NaP2P, 5 mM NaF, 5 mM EDTA, 150 mM NaCl, 1% NP-40,
50 mM Tris (pH 7.4), 50 mg/ml aprotinin and leupeptin]. Lysates
were precleared for 1 h at 4uC. Immunoprecipitation was
performed at 4uC overnight using 2 mg of the relevant antibodies.
Thereafter, lysates were incubated with protein G Sepharose
(Amersham-Pharmacia, Vienna) [for Streptactin IP, Streptactin
Beads were used] for 1 h at 4uC, extensively washed in lysis buffer,
resolved on an SDS–PAGE and immunostained for the relevant
protein.
Gel Mobility Shift Assays
Nuclear extracts were harvested from 16107 cells according to
standard protocols. Briefly, purified CD3+ T cells were washed in
PBS and resuspended in 10 mM HEPES (pH 7.9) 10 mM KCl,
0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT and protease
inhibitors. Cells were incubated on ice for 15 min. NP-40 was
added to a final concentration of 0.6%, cells were vortexed
vigorously, and the mixture was centrifuged for 5 min. The
nuclear pellets were washed twice and resuspended in 20 mM
HEPES (pH7.9), 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, and
1 mM DTT and protease inhibitors, and the tube was rocked for
30 min at 4uC. After centrifugation for 10 min, the supernatant
was collected. Extracted proteins (2 mg) were incubated in binding
buffer with [32P]-labeled, double-stranded oligonucleotide probes
(NFkB: 59-GCC ATG GGG GGA TCC CCG AAG TCC-39;
NFAT: 59-GCC CAA AGA GGA AAA TTT GTT TCA TAC
AG-39) (Nushift; Active Motif). In each reaction, 36105 c.p.m. of
labeled probe was used, and the band shifts were resolved on 5%
polyacrylamide gels. All experiments were performed at least three
times with similar outcomes.
Flow Cytometry
Single-cell suspensions from the spleen, lymph node and thymus
were prepared and incubated for 30 min on ice in staining buffer
(PBS containing 2% fetal calf serum and 0.2% NaN3) with FITC,
PE or APC antibody conjugates. Surface marker expression was
analyzed using a FACScanTM cytometer (Becton Dickinson & Co.,
Mountain View, CA) and CellQuestProTM software according to
standard protocols. Antibodies against murine CD3, CD4, and
CD8 were obtained from Caltag Laboratories; CD19, CD69,
CD44, and CD25 were obtained from BD PharMingen.
Retroviral Transduction of Primary Mouse T cells
The packaging cell line platE was transfected with a pMX
retroviral vector encoding an EGFP-Cyld fusion cDNA. Approx-
imately 36 h later, supernatants were collected and used directly to
infect 24 h to 48 h preactivated CD3+ cells using spin inoculation
(1 h, 20006g, 32uC), followed by a 5–6 h incubation period at
37uC. Infected cells were washed, resuspended in full supplement-
ed medium and incubated for an additional 48 h to 72 h. From
these cultures, GFP-expressing cells were analyzed using confocal
microscopy to track the subcellular distribution of the protein of
interest.
Monitoring CYLD Localization Using Confocal
Microscopy
CD3+ cells from wild type and PKCh/b knockout mice that were
transduced with a retrovirus expressing an EGFP-CYLD were not
stimulated or PDBu- and ionomycin-stimulated, transferred to a
polylysine-coated slide and fixed with 2% paraformaldehyde. After
permeabilization (0.1% TritonX-100 in PBS) and a blocking step
(5% goat serum in PBS), the cells were stained with Alexa595-
CTB (for lipid raft staining) and TOPRO 3 (Nucleus) (Molecular
Probes). Immunofluorescence was analyzed with a Zeiss LSM 510
confocal laser scanning microscope and Zeiss LSM software v3.2.
Statistical Analysis
Differences between genotypes were analyzed using the
unpaired Student’s t test.
Results
Overlapping Roles of PKCh and PKCb in NFkB and NFAT
Transactivation Processes in Primary Mouse CD3+ T cells
Studies using targeted gene disruption defined a critical role for
PKCh in the activation of the IL-2 promoter in the NFkB and
Ca2+/NFAT pathways [5,6]. Surprisingly, the phenotypic char-
acterization of PKCh-deficient T cells revealed a strong upregula-
tion of PKCb protein levels in PKCh single knockout T cells
(Fig. 1A). To investigate potentially compensatory and overlapping
roles of these two PKC family members in T cell activation
processes, PKCh/b double knockout mice were generated. These
mice were viable, fertile and breed at normal Mendelian ratios.
The null mutations for PKCh and PKCb were confirmed by PCR
and immunoblotting of whole cell lysates from naive thymocytes
and peripheral CD3+ T cells (Fig. 1B).
Flow cytometric analysis of thymocyte populations in PKCh/
b2/2double knockout mice revealed a slightly diminished
percentage of CD3-, CD4- and CD8-positive cells, comparable
to the PKCh single knockout phenotype and in agreement with
previous research [24,25], which might indicate an involvement of
PKCh in the positive selection process during thymocyte
development. Nevertheless, in the periphery, PKCh/b2/2 mice
revealed no gross differences in the distribution of CD3-, CD4-,
CD8-positive cells, leading to the conclusion that the concomitant
loss of PKCh and PKCb did not additively affect T cell development
(Table 1+ Table 2).
Examination of the stimulation-dependent upregulation of
CD25, CD69 and CD44 surface markers on CD4+ and CD8+
subsets revealed no gross differences in the total percentage of
positive cells between the genotypes, but the total protein amount
per cell, monitored by median fluorescence intensity, was strongly
reduced in PKCh/b2/2 and to an intermediate extend in PKC
singly-deficient T cells. These data might indicate a possible defect
in the upregulation of both the IL-2 receptor chain alpha (CD25)
and the activation marker CD69 in PKC-deficient T cells in both
CD4+ and CD8+ T cells (Fig. S1).
indicated phospho-specific and pan-antibodies. Protein phosphorylation levels were relatively quantitated by densitometric analysis. Numbers
beneath bands indicate fold change compared to wt control after normalization to FYN.
doi:10.1371/journal.pone.0053709.g003
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In contrast to the relatively normal T-cell development
observed, the T-cell response of peripheral T cells after TCR
stimulation was affected by the single and simultaneous loss of
PKCh and PKCb. The H3-thymidine uptake and IL-2 secretion
response of PKCh/b-deficient T cells stimulated with anti-CD3
and with or without anti-CD28-activated did not significantly
exacerbate the defects already observed in the absence of PKCh
alone (Fig. S2A–C). To exclude the proliferative defects being
caused by deregulated apoptosis, we analyzed the activation-
induced cell death (AICD) of CD4+ and CD8+ T-cell blasts
derived from wild-type and double knockout animals using CD3
engagement in vitro; in addition also the Fas ligand induced cell
death was monitored, but no enhanced apoptotic responses of
PKCh/b2/2 were detected (Fig. S3A–B).
However, analysis of the pathways leading to IL-2 transcription
revealed additively reduced binding of NFkB and NFAT to DNA
in PKCh/b double-deficient CD3+ T cells after CD3/CD28
stimulation (Fig. 1C). Immunoblot analysis of nuclear extracts
demonstrated that the weaker DNA binding of NFkB and NFAT
was due to the reduced nuclear entry of two NFkB subunits, p50
and p65, and NFAT upon stimulation (Fig. 1D). Activation of
NFkB involves the phosphorylation of I-kBa by IKKb and its
subsequent proteasomal degradation. Consistent with the additive
affect on NFkB translocation, the double knockout showed a
weaker I-kBa phosphorylation after stimulation with CD3/CD28.
Also the activation of the Map kinase pathway was partially
affected by PKCh/b deficiency, visible through a reduced ERK
phosphorylation, whereas the activation of Akt/PKB was normal
(Fig. 1E).
PKCh and PKCb Synergistically Regulate TAK1 and JNK
Activation
In agreement with the defective IKK/I-kBa axis, PKCh/b2/2
CD3+ cells revealed a drastic activation defect in TGF b activated
kinase 1 (TAK1), which is known to be a key regulator of IKKb
signaling. The loss of both PKC isotypes appears to be required to
abolish the signal, because TAK1 activation levels were similar
between the wild-type and PKC single knockout T cells (not
shown). Additionally, the JNK signal was attenuated by the
targeted disruption of PKCh and PKCb, whereas ERK1/2
activation was only marginally affected (Fig. 2A). Similar outcomes
were observed in PDBu- and ionomycin-stimulated primary
mouse wild-type T cells pretreated with 500 nM of a PKC-
specific low molecular weight inhibitor (PKC LMWI). The
stronger effect of the pharmacological pan-PKC inhibitor on
MAP kinase activation can be best explained by its established
inhibition of additional PKC family members next to PKCh and
PKCb (Fig. 2B).
Cyld2/2 T cells Show a Hyperactive Phenotype in NFkB
and NFAT Transactivation Responses
Since the deubiquitinating enzyme CYLD has been shown to be
a negative regulator of Tak1 [12] and JNK signaling [26], we
investigated a possible link between CYLD and the PKCh/b
isotypes in NFkb and NFAT driven IL-2 upregulation.
Despite of an observed thymocyte maturation defect, recent
work on T cell signaling in Cyld2/2 mice demonstrated hyper-
responsiveness to TCR stimulation by constitutive activation of
NFkB [12]. We confirmed these results, as we also observed that
Cyld2/2 T cells showed elevated activation-induced IL-2 responses
(Fig. 3A). This hyper-responsive IL-2 secretion correlated with an
increase of NFkB DNA binding to the IL-2 promoter in the
nuclear fractions of stimulated Cyld-deficient T cells (Fig. 3B) and
hyper-phosphorylated I-kBa levels in the cytosol compared to
wild-type controls (Fig. 3C). Interestingly, and in accordance with
a previous publication [27], we determined that CYLD also acts as
a negative modulator of the NFAT pathway. The examination of
NFAT transactivation using immunoblot and EMSA technology
revealed increased nuclear translocation and subsequent binding
of NFAT to DNA in Cyld-deficient cells (Fig. 3B). Our EMSA
result was confirmed by the elevated activation status of
phospholipase Cc1, which has been identified as a key regulator
of Ca2+/Calcineurin/NFAT signaling. However, ERK signaling
was not affected by the loss of Cyld (Fig. 3C).
Association of CYLD with PKCh
Considering the reciprocal phenotypes of Cyld- and PKCh/b-
deficient T cells involving NFAT and NFkB transactivation we
investigated a potential direct interaction between this enzymes.
Interestingly and indeed, we identified a physical and functional
PKCh-CYLD interaction in the cytosol of primary T cells. The co-
immunoprecipitation analysis of CYLD and the PKCh isotype
from cell extracts of unstimulated and CD3/CD28-activated
peripheral CD3+ cells revealed that PKCh and CYLD physically
associate in a complex in resting conditions (Fig. 4A). Next, we
mapped the PKCh interaction domain in the CYLD protein by
co-transfection of HEK293T cells with a vector encoding PKCh
and with vectors expressing full-length Flag-tagged wild-type or N-
and C- terminally truncated forms of CYLD (encoding residues 1–
212, 318–956 and 587–986 of CYLD). The CYLD pull down with
a specific Flag antibody revealed increased binding of PKCh to
CYLD mutants containing the deubiquitinase domain (Fig. 4B).
We observed identical results when the co-immunoprecipitation
was performed to precipitate PKCh. A strep-tagged PKCh
construct was co-transfected with the Flag-tagged CYLD con-
structs. A GFP control for each CYLD construct was included to
identify unspecific binding to the Streptactin-beads. PKCh
precipitation confirmed that the C-terminal part of CYLD is
necessary for complex formation between the two interacting
protein (Fig. 4C).
In Jurkat Cells, CYLD is Cleaved by MALT1 in a PKC-
dependent Mechanism
When Jurkat cells overexpressing an N-terminally HA-tagged
CYLD construct were stimulated for 30 min with PDBu and
ionomycin, a CYLD fragment of approximately 40 kDa was
Figure 4. Association of CYLD with PKCh. (A) CYLD directly interacts with PKCh in primary mouse CD3+ cells. The complex is formed
constitutively and is not affected by TCR activation. One representative experiment of three is shown. The C-terminal region of CYLD is important for
interaction with PKCh. (B) Co-immunoprecipitation of PKCh using CYLD pulldown. Increased binding of PKCh to the C-terminus of CYLD was shown in
HEK293T cells transiently co-transfected with vectors encoding PKCh (PEFneo) and a full-length Flag-tagged wild-type CYLD, N- or C-terminally
truncated forms of CYLD (residues 1–212, 318–956 and 587–986 of CYLD). Untransfected and GFP-transfected controls were included. One
representative experiment of three is shown. A schematic representation depicts the CAP-Gly and peptidase domains in wild-type and truncation
mutants of CYLD. (C) Co-immunoprecipitation of CYLD using PKCh pulldown. A strep-tagged full-length PKCh construct was co-transfected with Flag-
tagged CYLD constructs into HEK293T cells. As previously, the importance of the C-terminal region of CYLD for binding is shown. GFP controls for
each CYLD construct were included. One representative experiment of three is shown.
doi:10.1371/journal.pone.0053709.g004
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Figure 5. CYLD is endoproteolytically processed in the Jurkat cell line and in primary human T cells. (A) The essential role of both the
catalytic activity of PKC and MALT1 for activation-dependent CYLD cleavage. Jurkat cells transfected with HA-tagged Cyld vectors were activated by
PDBu and ionomycin in the presence of PKCh and MALT1 pharmacological inhibitors. After 20 min, cells were lysed and fractionated into membrane
(m), cytosolic (c) and nonsoluble (ns) fractions. CYLD and its clipping product were present in (c), inhibition of PKCh and MALT1 activity blocks CYLD
cleavage. (B) CYLD processing occurred also under endogenous conditions in stimulated primary human T cells isolated from whole blood samples;
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detected using the anti-HA antibody. Because the administration
of PDBu mimics TCR signaling by activating PKC family
members, we wanted to identify a role for PKC in this cleavage
event. Therefore, Jurkat cells were pretreated with the specific
pan-PKC pharmacological inhibitor, which resulted in the
disappearance of this fragment (Fig. 5A). This finding emphasized
that the endoproteolytic cleavage of CYLD is PKC dependent. We
also isolated primary T cells from human whole blood and
analyzed the CYLD processing under endogenous conditions. In
addition, human T cells were treated with the pan-PKC inhibitor
to investigate the PKC dependency in this process. Comparable to
the results with Jurkat cells, CYLD underwent a stimulation
dependent processing also in primary human T cells, which could
be blocked by PKC inhibition. The generation of a 40 kDa NH2-
terminal and a 70 kDa C-terminal cleavage fragment was
confirmed via the use of NH2- and C-terminus recognizing
specific CYLD antibodies (Fig. 5B).
Because Coornaert et al. showed that the paracaspase MALT1
directly cleaved the deubiquitinating protein A20 to generate a
fragment with a smaller molecular size in stimulated T cells [28],
we asked if MALT1 was also responsible for the cleavage of CYLD
by treating Jurkat cells with the tetrapeptide inhibitor z-VRPR-
fmk, which has been shown to inhibit specifically the MALT1
protease activity [29]. As a result, cells treated with the MALT1
inhibitor showed a reduced CYLD cleavage after activation
(Fig. 5A).
Based on the size and the molecular weight of the CYLD N-
terminal 40 kDa proteolytic fragment, we identified the cleavable
arginine residue at position 324 in the human CYLD protein and
generated a Cyld mutant with alanine substituted for arginine at
position 324 (Cyld-R324A). Next, we investigated if this mutant
was cleavable when overexpressed in Jurkat cells or was resistant to
proteolysis. Wild-type CYLD was processed after stimulation,
whereas the mutant could no longer be cleaved (Fig. 5C). This led
to permanent inhibition of the NFkB pathway by the inactivation
resistant CYLD mutant and result in slightly diminished
phosphorylation of I-kBa. The MAPK pathway was not affected
by the expression of uncleavable CYLD.
Because NFkB is important for IL-2 upregulation in activated T
cells, we tested the influence of the protease-resistant Cyld mutant
on IL-2 transactivation using an IL-2-promoter-dependent lucif-
erase assay. The diminished NFkB signal observed by immunoblot
was correlated with impaired IL-2 transcription (Fig. 5D). This
provides experimental evidence that CYLD processing, which
leads to an inactivation of its repressor function within a positive
feedback loop, is an important prerequisite for robust IL-2
activation. Consistent with our investigation of CYLD cleavage
at arginine 324 in the Jurkat tumor cell line, Staal et al.
independently published that TCR-induced JNK activation
required CYLD proteolysis by MALT1 [18]. Nevertheless, our
findings extend the function of CYLD cleavage to NFkB
activation. To identify the physiological role of this candidate
process, we examined primary CD3+ T cells derived from wild-
type and knockout mice.
PKC-dependence, Cleavage Site and Kinetics of CYLD
Cleavage Differ in Primary Mouse T cells
Stimulation induced a CYLD fragment not only in human cells
but also in primary mouse T cells. Interestingly activation of
primary mouse T cells by CD3 with or without CD28
costimulation generated a NH2-terminal CYLD fragment of
approximately 25 kDa, smaller in size than the human fragment
(Fig. 6A), implicating a different cleavage site in the mouse CYLD
protein. Although we did not determine the exact cleavage site,
arginine 235 was the best candidate for the cleavage site.
Importantly, the fragment was first detectable after 4 h of
stimulation, indicating different kinetics leading to CYLD
inactivation in primary mouse cells. Unexpectedly, PKCh/b-
deficient T cells showed normal CYLD processing after stimula-
tion, implicating additional protein kinases in this process (Fig. 6B).
As a consequence, the activation defects of the TAK1/IKK axis in
PKCh/b-deficient T cells cannot solely be explained by CYLD
inactivation.
Alternatively, the existence of a constitutive CYLD/PKCh
complex might suggest that PKCh, which shows activation-
dependent subcellular translocation, is important for removing
CYLD from its NFkB-related targets and attenuates the negative
regulatory function of CYLD, enabling feedback control of NFkB
activation. To address this hypothesis, we analyzed the subcellular
distribution of a retrovirally introduced mutant CYLD-GFP fusion
protein in unstimulated and stimulated wild-type and PKCh/b-
deficient T cells with confocal microscopy. CD3+ T cells from both
genotypes were retrovirally infected with a CYLD-GFP fusion
construct, and the colocalization of CYLD-GFP with lipid rafts
was monitored with Cholera Toxin B. Interestingly, CYLD
colocalization with lipid rafts was strongly diminished in PKCh/b-
deficient T cells compared to control cells, suggesting PKC-
dependent CYLD membrane shuttling. A statistically significant
decrease in CYLD translocation in double knockout cells was
detected in unstimulated cells, whereas after 15 min of PDBu and
ionomycin stimulation, CYLD translocation to the membrane was
observed in both wild-type and knockout cells (Fig. 6C).
Discussion
Numerous studies emphasize PKChs key role as a regulator of
NFkB and Ca2+/NFAT signaling in T cells downstream of the
TCR [5,6,30–32]. The PKCb isotype is also expressed in T cells.
However, PKCb-deficient primary mouse T cells have a fairly
normal activation response [33], although Volkov et al. estab-
lished a major role for PKCb in LFA1-dependent T-cell
locomotion [34,35].
Our recent work defines a redundant role for both the novel
PKCh variant and the classical isotype PKCb in the NFkB and
NFAT signaling pathways. T cells isolated from PKCh/b-deficient
mice had a stronger impairment in NFkB and NFAT nuclear
entry and DNA binding compared to CD3+ T cells from control
and single knockout mice. Impaired TAK1 activation in double-
deficient T lymphocytes is the best candidate for restricted IKK/
IkBa signaling. Functional redundancy of PKCh with other
members of the PKC family in NFkB and/or NFAT activation
has been shown in previous studies. For instance, stimulation-
PKC dependency of this process was verified by pan-PKC LMWI treatment. The generation of a 40 kDa NH2-terminal and a 70 kDa C-terminal cleavage
fragment was confirmed via the use of NH2- and C-terminus recognizing specific CYLD antibodies. (C) Mapping of the R234 cleavage site in CYLD
using site-directed mutagenesis. The cleavage-resistant CYLD mutant R324A, when overexpressed in Jurkat cells, is not cleaved and leads to an
increased suppression of NFkB-driven signals (as detected by the decreased phosphorylation of IkBa. (D) PKC- and MALT1-induced proteolysis at
R234 appears critical for complete IL-2 promoter transactivation, shown by an IL-2 promoter luciferase assay.
doi:10.1371/journal.pone.0053709.g005
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Figure 6. CYLD cleavage in primary mouse T cells shows a different kinetic. (A) CYLD cleavage in primary mouse cells has different kinetics.
The activation of primary mouse T cells by CD3 with or without CD28 costimulation leads to the formation of an NH2-terminal CYLD fragment of
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dependent colocalization of atypical PKCf/i with PKCh in the
lipid raft fraction of T lymphocytes leads to cooperation of these
isotypes in modulating the NFkB signaling pathway [36]. The
collaborative activity of PKCh and PKCa in the NFAT pathway
was examined in a PKCa/h double knockout mouse strain.
Compared to PKCa and PKCh single-deficient T cells, double-
deficient CD3+ cells showed additively reduced IL-2 secretion
levels correlated with strongly impaired nuclear translocation and
DNA binding of NFAT after stimulation. Of note, the PKCa/h
double knockout mice showed an impaired alloimmune response,
leading to significantly prolonged allograft survival in heart
transplantation experiments [37].
Similar to phosphorylation, K63 ubiquitination is a reversible
process that influences protein activity, trafficking and signaling
complex assembly. The removal of ubiquitin chains is mediated by a
family of deubiquitinases, of which the cylindromatous gene
product CYLD and the Tumor necrosis factor a-induced protein
3, also called A20, is currently receiving broad scientific attention.
Both CYLD and A20 have been implicated as a modulator of the
activity of NFkB-related molecules, such as NEMO (IKKc),
TRAF2 and TRAF6 [38–40]. Both enzymes overlap functionally
by targeting a similar set of substrates, which was explained by the
different expression pattern of A20 and CYLD. A20 function
depends on its transcriptional upregulation, whereas CYLD is
constitutively expressed, influencing the different time windows of
NFkB activation differently. However, a constitutive expression and
activity pattern requires a posttranslational regulatory mechanism
to inactivate the repressor during signal-induced NFkB signaling.
The cleavage-dependent inactivation of a deubiquitinase as a
posttranslational regulatory mechanism in activated T cells was first
described by Coornaert et al. [28], in which A20 was defined as a
MALT1 substrate, which upon antigen receptor engagement
undergoes cleavage for functional NFkB signaling. In our study,
we showed that PKCh and CYLD are constitutively bound in a
physical complex in the cytosol of primary mouse CD3+ cells. Direct
crosstalk between CYLD and a PKC family member has not been
described to date; therefore, we aimed to elucidate the biological
relevance of this protein-protein interaction in T-cell signaling by
examining genetic knockout mouse models in combination with
selective pharmacological inhibitors. The reciprocal phenotypes of
T-cell signaling pathways in Cyld2/2 and PKCh/b2/2 mice
prompted us to analyze the activity of key molecules linked to
NFkB and NFAT transactivation to uncover a regulatory mecha-
nism to address the modulation of TAK1 activity In agreement with
Koga et al. [27], who demonstrated negative regulation of NFAT
activity by CYLD via the TAK1/MKK3/6/p38a/b axis, our
experimental data clearly attest to CYLD involvement in NFAT
activity modulation downstream of TCR signaling.
Our results show that PKC, particularly the PKCh/b isotypes,
can influence CYLD repressive activity in different ways. In the
human Jurkat leukemic T-cell line, PKC enzymatic activity was
important for rapid MALT1-dependent CYLD processing, which is
required for TCR-linked NFkB transactivation and leads to
functional IL-2 induction. The requirement for MALT1-mediated
CYLD cleavage for intact JNK signaling downstream of the TCR
has been previously described [18]. Thus, proteolytic inactivation of
CYLD affected IL-2 transactivation via the JNK/AP1 pathway;
here, we provide experimental evidence that NFkB activity is also
specifically dependent on CYLD cleavage, subsequently modulating
IL-2 signals. Of note, we independently confirmed arginine 324 as
the CYLD cleavage site. Recently, caspase 8 has been shown to
cleave CYLD at aspartate 215 in Jurkat cells following TNFa
stimulation, generating a pro-survival signal to save the cells from
necrotic cell death [41]. Additionally, phosphorylation of CYLD
was found to downregulate CYLD activity: transient phosphoryla-
tion by IKK in a serine cluster just upstream of the TRAF2 binding
site, attenuates DUB function [42]. However, NFkB itself can
regulate CYLD expression in a negative feedback loop [43].
In primary T cells isolated from PKCh/b deficient mice, CYLD
was processed to the same extent as in wild-type control cells.
Additionally, the kinetics of CYLD cleavage was different in
mouse T cells compared to Jurkat cells, starting approximately 4
hours after stimulation, later then the rapid response through
TAK1 activation. The different requirement for PKC and the
altered kinetics in the mouse system led to the analysis of the
stimulation-dependent spatial and temporal organization of the
PKCh/CYLD complex using immunofluorescence microscopy.
Interestingly, we found decreased CYLD lipid raft localization in
PKCh/b-deficient T cells under resting conditions, likely affecting
activation-induced signaling.
Conclusion
We observed a direct functional connection between the positive
PKCh/b and the negative CYLD signaling pathways that fine-tune
TCR/CD28-induced signaling responses. Our findings suggest the
following scenario: PKCh/b are the essential kinases in a
physiological signaling cascade that is necessary to counteract
CYLD-mediated repression of NFkB and NFAT transactivation.
This direct and physical antagonistic crosstalk between the PKC-
derived signals and the CYLD-derived signals might represent one
mechanism of how antigen-receptor-dependent fine-tuning of the
amplitude of T lymphocyte activation is processed.
Supporting Information
Figure S1 Effect of PKCh/b deficiency on CD25, CD44,
and CD69 surface expression. T cells were stimulated for
16 h by CD3/CD28 ligation and the surface expression of CD25,
CD44, and CD69 for CD4+ and CD8+ subsets were measured by
flow cytometry. The relative fluorescence intensities are indicated
as the median fluorescence intensity. The results shown are the
mean6SE of three independent experiments.
(TIF)
Figure S2 Proliferative and cytokine secretion respons-
es of PKCh/b CD3+ T cells. (A, B) Proliferative responses of
PKCh/b and PKCh-deficient CD3+ T cells were analyzed in
comparison to wild-type littermate controls. After incubation using
different stimulatory conditions (antibodies or BALB/C spleno-
cytes), cells were analyzed using standard procedures for
thymidine incorporation. (C) IL-2 cytokine secretion by knockout
CD3+ T cells was analyzed in comparison to wild-type littermate
controls. After stimulation with anti-CD3 with or without soluble
approximately 25 kDa. In stark contrast to the rapid kinetics in Jurkat cells, the fragment was first detected after 4 h of stimulation. (B) Primary mouse
T cells from PKCh/b2/2 mice showed normal stimulation-dependent CYLD cleavage, comparable to wild-type control mice. (C) Analysis of the
subcellular distribution of a retrovirally introduced CYLD-GFP fusion mutant in unstimulated and stimulated wild-type and PKCh/b-deficient T cells.
(green): the co-localization with Cholera Toxin B stained lipid rafts (red) was monitored using confocal microscopy. Nuclei are stained in blue.
Quantification of CYLD-lipid rafts co-localization is shown in the bars in the right panel and reveals a statistically significant decrease in CYLD
translocation in unstimulated double knockout cells in comparison to wt control cells. *p,0.05; **p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0053709.g006
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anti-CD28, supernatants were analyzed for IL-2 concentration
using Bioplex suspension array technology. One representative
experiment of three is shown.
(TIF)
Figure S3 Activation-induced cell death (AICD) of CD4+
and CD8+ T cell blasts derived from double knockout
animals was not increased compared to cells from single
knockout littermates. (A, B) AICD was induced by different
concentrations of anti-CD3 for 8 hours. The results shown are the
means of three independent experiments.
(TIF)
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